07.09.13
Amgen and Servier have entered a new R&D collaboration in cardiovascular disease. Amgen has obtained U.S. commercial rights to Servier's oral drug, approved in the EU as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates, as well as an exclusive option to develop and commercialize Servier's investigational molecule, S38844, currently in Phase II development for the treatment of heart failure.
Additionally, Servier has obtained rights to commercialize cardiac myosin activator omecamtiv mecarbil in Europe. It is currently being tested for potential applications in heart failure in patients with systolic dysfunction. Both companies can exercise their respective options following Phase II studies. Amgen will make a $50 million upfront payment and future milestone and royalty payments for ivabradine. Other financial terms were not disclosed.
"Amgen is pleased to enter into this collaboration with Servier to bring potential new cardiovascular treatment options to patients in both the U.S. and Europe," said Sean E. Harper, M.D., executive vice president of R&D at Amgen. "A critical unmet medical need remains for patients who don't respond adequately to current available therapies for heart failure and angina. We value Servier's extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area."
Additionally, Servier has obtained rights to commercialize cardiac myosin activator omecamtiv mecarbil in Europe. It is currently being tested for potential applications in heart failure in patients with systolic dysfunction. Both companies can exercise their respective options following Phase II studies. Amgen will make a $50 million upfront payment and future milestone and royalty payments for ivabradine. Other financial terms were not disclosed.
"Amgen is pleased to enter into this collaboration with Servier to bring potential new cardiovascular treatment options to patients in both the U.S. and Europe," said Sean E. Harper, M.D., executive vice president of R&D at Amgen. "A critical unmet medical need remains for patients who don't respond adequately to current available therapies for heart failure and angina. We value Servier's extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area."